Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 198,500 shares, a decrease of 15.3% from the February 28th total of 234,400 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily […]
Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy,.
Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered SuperkinesDelivery of selected Bcl-2.
Analysts expect Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating) to announce earnings of ($0.08) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Medicenna Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.07). Medicenna Therapeutics posted earnings of ($0.09) per […]